Japanese encephalitis virus SA14-14-2 precursor membrane and envelope proteins (JEV SA14-14-2 prM/E)

The Japanese encephalitis virus (JEV) SA14-14-2 prM/E antigens are the primary structural components of the live-attenuated SA14-14-2 vaccine strain, which is used globally to prevent Japanese encephalitis [1][2]. The envelope (E) protein is the major immunogen and is responsible for critical steps in the viral life cycle, including binding to host cell receptors and mediating membrane fusion [2][3]. The precursor membrane (prM) protein acts as a chaperone, ensuring the correct folding and assembly of the E protein into mature, infectious virions [3]. When these antigens are introduced via vaccination, they stimulate the adaptive immune system to generate long-lasting memory B cells and T cells [1][4]. The resulting neutralizing antibodies specifically target the domain III of the E protein, effectively blocking the virus from entering central nervous system cells and preventing the severe neuroinflammation associated with wild-type JEV infection [2][3]. The original target name provided is considered incorrect as it describes a complex physiological process (the adaptive immune response) rather than a specific molecular target entity [1].

Other names

JEV prM/E antigensJapanese encephalitis virus envelope proteinJapanese encephalitis virus precursor membrane proteinSA14-14-2 structural proteinsJEV E protein

Induction of neutralizing antibodies (primarily targeting the E protein) and activation of CD4+ and CD8+ T-cell responses to prevent viral entry and replication in host cells.